Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). According to GlobalData, Phase II drugs for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Safinamide mesylate LoA Report. Buy the report here.
Zambon Presents Results from the Two Phase 3 PROMIS Studies of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis at World Bronchiectasis Conference 2023
MILAN and BOSTON, May 8, 2023 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, today announced the presentation of data from a health economic outcomes study characterizing the lifetime burden of illness for U.S. patients diagnosed with bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HSCT) or lung transplantation at the 2023 Virtual International Society for the Pharmacoeconomic and Outcomes Research (ISPOR) conference being held from May 7-10 in Boston, MA.
Zambon has completed the patient enrolment of patients in its two pivotal Phase III trials of Liposomal Cyclosporine A for Inhalation (L-CsA-i) to treat bronchiolitis obliterans syndrome (BOS).
MILAN and BOSTON, May 1, 2023 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, announced today that the Company has completed enrollment in its two pivotal Phase 3 studies. The trials are designed to evaluate the safety and efficacy of Liposomal Cyclosporine A for Inhalation (L-CsA-i) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTON-2) transplantation.
Zambon and IMA Active: paving the way towards process optimisation
MILAN and BOSTON, Oct. 14, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, announced today that the Company will present findings examining how Chronic Lung Allograft Dysfunction (CLAD) is the leading cause of re-transplantation and associated with high healthcare costs during a rapid oral session at the American College of Chest Physicians® (CHEST) 2022 Annual Meeting being held October 16 – 19, 2022 in Nashville, TN.
MILAN and BOSTON, May 12, 2022 /PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people's health and the quality of patients' lives, today announced that the Company will attend the American Thoracic Society (ATS) 2022 Annual Meeting being held May 13 - 18, 2022 in San Francisco, CA. Zambon representatives will be at booth #10 in the ATS 2022 Clinical Trials Awareness Area to discuss advancements in the Company's two Phase 3 development programs for the treatment of non-cystic fibrosis bronchiectasis (NCFB) and bronchiolitis obliterans syndrome (BOS), two severe respiratory diseases with high unmet medical needs.
MILAN--(BUSINESS WIRE)-- Zambon, a pharmaceutical company on a mission to innovate cure & care to make patients’ lives better, is pleased to announce the final results from the Phase 3 PROMIS-I study, which were presented at the European Respiratory Society Congress today.